Factors Affecting the Results of Superficial Femoral Artery Stenting

Abstract

Introduction:

The aim of this study was to assess the durability of superficial femoral artery (SFA) stents and factors that affect stent patency.

Methods:

A retrospective assessment of 214 SFA stent procedures between 2003 and 2012 was conducted from a prospectively compiled database. Patency rates and patient outcomes were compiled from case notes and computerized records. Stent patency was confirmed by either duplex scan or clinical examination (palpable distal pulse). Survival and patency were compared across a range of factors using Kaplan-Meier plots and log-rank tests. Factors found to be significant were further assessed by Cox regression models.

Results:

Data were analyzed for 214 limbs in 205 patients. Inclusion criteria included those patients who received an SFA stent for treatment of claudication or critical limb ischemia (CLI) with follow-up data. This gave a study group of 151 limbs divided into 76 claudicant and 75 patients with CLI (male–female ratio = 103:48, mean age 71 years, standard deviation 11.7). Seventy-one percent of procedures were elective and 29% were emergency procedures; 53% of procedures were carried out on a day case basis. Median follow-up was 11 months (range 1 day-89 months). Patency was significantly worse for patients with CLI (P = .009), with a 1- and 3-year patency of 63% and 34% compared to 79% and 60% in patients with claudication. Significant factors associated with patency included oral therapy controlled diabetes (P = .003), lesions located in either the mid-SFA (P = .029) or the mid-popliteal (P = .013), and periprocedural complications (P = .005). There was no significant difference in patency rates between insulin-dependent and nondiabetic patients (hazard ratio: 1.0, 95% confidence interval: 0.4-5.6, P = .983). The overall amputation rate for the total study group was 5%. Patients with 1- and 3-year survival were 98% and 96% in the claudication group and 74% and 51%, respectively, in the CLI group.

Conclusion:

SFA stents have superior outcomes in claudicants. Patency is related to severity of disease, diabetes, and location of disease.

Keywords

superficial femoral artery stent popliteal artery

Get full access to this article

View all access options for this article.

References

Becquemin

Favre

Marzelle

Nemoz

Corsin

Leizorovicz

. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37(3):487–494.

Cejna

Thurnher

Illiasch

. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12(1):23–31.

Bosiers

Torsello

Gissler

. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16(3):261–269.

Dake

Ansel

Jaff

; Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61(24):2417–2427.

Tetteroo

van der Graaf

Bosch

. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998;35(9110):1153–1159.

Adam

Beard

Cleveland

; BASIL trial participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925–1934.

Young

MStreicher

Beck

van den Bogert

Tajaddini

Davis

. Simulation of lower limb axial arterial length change during locomotion. J Biomech. 2012;45(8):1485–1490.

Wensing

Scholten

Buijs

. Arterial tortuosity in the femoropopliteal region during knee flexion: a magnetic resonance angiographic study. J Anat. 1995;187(pt 1):133–139.

Smouse

Nikanorov

LaFlash

. Biomechanical Forces in the Femoropopliteal Arterial Segment. What happens during extremity movement and what is the effect on stenting? Endovascular Today. 6 2005:60–66.

10.

Scheinert

Sax

. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–315.

11.

Schlager

Dick

Sabeti

Amighi

. Long-Segment SFA stenting—the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12(6):676–684.

12.

Nishibe

Kondo

Dardik

Muto

Koizumi

Nishibe

. Stent placement in the superficial femoral artery for patients on chronic hemodialysis with peripheral artery disease. Int Angiol. 2009;28(6):484–489.

13.

Bakken

Protack

Saad

. Impact of chronic kidney disease on outcomes of superficial femoral artery endoluminal interventions. Ann Vasc Surg. 2009;23(5):560–568.

14.

Kawamura

Ishii

Aoyama

. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis. J Vasc Surg. 2009;50(5):1057–1062.

15.

Laird

Katzen

Scheinert

. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery. Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–276.

16.

Dake

Ansel

Jaff

. Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. 2-Year follow-Up from the Zilver PTX Randomized and Single-Arm Clinical Studies. J Am Coll Cardiol. 2013;61(24):2417–2427.

17.

Visonà

Tonello

Zalunardo

. Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. Blood Transfus. 2009;7(1):18–23.

18.

Hanna

. Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization. J Invasive Cardiol. 2012;24(12):679–684.